EMA panel backs approval of Revolution's pancreatic cancer drug | Reuters

Revolution Medicines wins EU panel backing for pancreatic cancer drug Rasonque

The European Medicines Agency's advisory committee recommended approval of Revolution Medicines' Rasonque for adults with metastatic pancreatic cancer that has progressed after at least one prior therapy.